



**A targeted ADT,
reducing cardiac risk
vs. LHRH agonists³⁻⁸**



**with over 30% discount on the NHS list price⁹
from 1st January 2025**

A trusted and familiar brand, FIRMAGON[®] is a GnRH antagonist – a different class of ADT to the traditionally used LHRH agonists.¹⁰

**Same familiar product, with the same indications,
at a lower cost:⁹**

INITIATION DOSE



FIRMAGON 120mg

**First month of treatment
is 2 x 120 mg¹**

with

32.26% discount*

NHS cost per pack:⁹ £176.12

Cost for full loading dose
of 2 x 120mg injections for
first month:^{1,9} £176.12

MAINTENANCE DOSE



FIRMAGON 80mg

**Monthly administration from
second month is 1 x 80 mg**

with

31.2% discount*

NHS cost of monthly
maintenance dose:^{2,9} £89.01

Annual cost after
initial year: £1,068

*From 1st January 2025



**How much could your prostate cancer service
save on its FIRMAGON[®] prescriptions?**


**Below is a summary of the benefits FIRMAGON[®] can offer
patients with advanced prostate cancer vs. LHRH agonists:**



Reduced risk of CV events in patients with pre-existing CVD³⁻⁸



Improvement in overall survival rates¹¹



Delays PSA failure or death by 7 months, and **increases PSA progression-free survival** at 1 year, **sustained** to 5 years in **high-risk patients^{11-13**}**



Significant reduction in disease-related symptoms, improving QoL (reduces joint, musculoskeletal and urinary tract events)^{11,14}



82% patient satisfaction with FIRMAGON[®] administration at 6 months, **improved to 83.6% at 12 months¹⁵**

**High-risk defined as baseline PSA>20ng/ml

**Prescribe FIRMAGON[®] for your suitable patients - a
trusted, familiar brand that can save your centre over
30% on the NHS list price from 1st January 2025^{1,2,9}**

For further resources scan the QR code or visit the new
website <https://hcp.ferring.co.uk/urology/firmagon>



SCAN ME

Prescribing information for FIRMAGON[®] can be found
[**here**](#) or scan the QR code



SCAN ME

Adverse events should be reported.
Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk>.
Adverse events should also be reported to Ferring Pharmaceuticals Ltd.
Tel: 0800 111 4126. Email: medical@ferring.com

Abbreviations: ADT, androgen deprivation therapy; CV, cardiovascular; CVD, cardiovascular disease; GnRH, gonadotrophin-releasing hormone; LHRH, luteinising hormone releasing-hormone; PCa, prostate cancer; QoL, quality of life.

References: 1. FIRMAGON[®] 120 mg injection Summary of Product Characteristics. Ferring Pharmaceuticals Ltd. October 2022. Available at: <https://www.medicines.org.uk/emc/product/6537>. Last accessed: December 2024. 2. FIRMAGON[®] 80 mg injection Summary of Product Characteristics. Ferring Pharmaceuticals Ltd. October 2022. Available at: <https://www.medicines.org.uk/emc/product/6535>. Last accessed: December 2024. 3. Albertsen PC, *et al.* Eur Urol 2014;65:565–573. 4. Davey P and Kirby MG. World J Urol 2021;39:307–315. 5. Margel D, *et al.* J Urol 2019;202(6):1199–1208. 6. Perrone V, *et al.* Ther Clin Risk Manag 2020;16:393–401. 7. Cone EB, *et al.* J Clin Oncol 2020;38:6 Suppl 34. 8. Zhang KW, *et al.* J Urol 2021;206:613–622. 9. BNF. FIRMAGON[®]. Available at: <https://bnf.nice.org.uk/drugs/degarelix/medicinal-forms/>. Last accessed: December 2024. 10. Drudge-Coates L. Int J Urol Nurs 2009;3(3):85–92. 11. Klotz L, *et al.* Eur Urol 2014;66:1101–1108. 12. Boccon-Gibod L, *et al.* Ther Adv Urol 2011;3:127–140. 13. Crawford DE, *et al.* Urology 2014;83:1122–1128. 14. Mason M, *et al.* Clin Oncol 2013;25:190–196. 15. Roshani H, *et al.* Curr Urol 2021;15:204–208.



Date of preparation: April 2025
UK-FN-2500010